Just to put things in perspective, the Zack's report on RVX from April 2015 had a "hold" rating and price target of $3.25.

Just a reminder, tomorrow kicks off the 5-day barrage for RVX (and Zenith): ASN Kidney week, CTAD Alzheimer's Trial conference, American Heart Association, and AACR Cancer conference.

Regardless of the impact of the new Zack's report on the share price, it is great to have an updated (even if it's paid for by RVX) analyst report on RVX to help communicate the latest and greatest with Resverlogix. The science conference barrage between tomorrow and Sunday will hopefully excite new investors to take a look at RVX and evaluate whether they want to come on board. The new Zack's report from yesterday will at the very least provide a quick reference source for those new to the company to learn more about Resverlogix.

BearDownAZ